, Volume 72, Issue 4, pp 326-328
Date: 05 Apr 2013

Disease modification in systemic sclerosis

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Despite intense efforts and significant advances in the management of organ-specific involvement and symptoms, systemic sclerosis (SSc) remains the autoimmune rheumatic disease with the highest progression and related mortality. The major perceived reason is the unavailability of successful disease-modifying (DM) therapeutic modalities [1].

We can argue that there are several reasons for the lack of success, such as the relative rarity and the complex physiopathology of the disease, its clinical heterogeneity and the weakness of current quantitative and unbiased assessment tools to evaluate the efficacy of therapeutic interventions, which of course limit the design and performance of informative clinical trials [2, 3]. However, based on recent advances, especially regarding pathophysiological mechanisms and reliable tools to detect the early stages of the disease, it now seems possible that new integrated approaches might offer a more successful modality to achieve and document DM treat ...